BR112013024169A2 - método para o tratamento e prevenção da doença de parkinson - Google Patents
método para o tratamento e prevenção da doença de parkinsonInfo
- Publication number
- BR112013024169A2 BR112013024169A2 BR112013024169A BR112013024169A BR112013024169A2 BR 112013024169 A2 BR112013024169 A2 BR 112013024169A2 BR 112013024169 A BR112013024169 A BR 112013024169A BR 112013024169 A BR112013024169 A BR 112013024169A BR 112013024169 A2 BR112013024169 A2 BR 112013024169A2
- Authority
- BR
- Brazil
- Prior art keywords
- parkinson
- disease
- prevention
- treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
- C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161472961P | 2011-04-07 | 2011-04-07 | |
PCT/US2012/032544 WO2013101281A1 (en) | 2011-04-07 | 2012-04-06 | Methods and compositions for treating parkinson's disease |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112013024169A2 true BR112013024169A2 (pt) | 2016-12-06 |
Family
ID=48698489
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112013024169A BR112013024169A2 (pt) | 2011-04-07 | 2012-04-06 | método para o tratamento e prevenção da doença de parkinson |
Country Status (11)
Country | Link |
---|---|
US (1) | US20140066434A1 (pt) |
EP (1) | EP2694066A1 (pt) |
JP (1) | JP2014513078A (pt) |
KR (1) | KR20140022062A (pt) |
CN (1) | CN103596568A (pt) |
AU (1) | AU2012363094A1 (pt) |
BR (1) | BR112013024169A2 (pt) |
CA (1) | CA2832465A1 (pt) |
EA (1) | EA201391486A1 (pt) |
MX (1) | MX2013011589A (pt) |
WO (1) | WO2013101281A1 (pt) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA3022250A1 (en) | 2012-12-12 | 2014-06-12 | Ariad Pharmaceuticals, Inc. | Crystalline forms of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-n-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide mono hydrochloride |
AU2013204506B2 (en) * | 2012-12-13 | 2016-05-05 | Ariad Pharmaceuticals, Inc. | Crystalline forms of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide mono hydrochloride |
CN104341416B (zh) * | 2013-07-31 | 2017-03-29 | 南京圣和药业股份有限公司 | 蛋白酪氨酸激酶抑制剂及其应用 |
GB2518873A (en) * | 2013-10-03 | 2015-04-08 | Agency Science Tech & Res | Bicyclic alkyne derivatives and uses thereof |
WO2015076213A1 (ja) * | 2013-11-22 | 2015-05-28 | 独立行政法人国立成育医療研究センター | 急性リンパ芽球性白血病の新規キメラ遺伝子atf7ip-pdgfrb |
CN104650086A (zh) * | 2013-11-22 | 2015-05-27 | 天津市汉康医药生物技术有限公司 | 盐酸帕纳替尼化合物 |
WO2015085973A1 (en) * | 2013-12-09 | 2015-06-18 | Zentiva, K.S. | Modifications of 3-(2-imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-n-[4-[(4-methyl-1-piperazinyl)methyl]-3-(trifluoromethyl)phenyl] benzamide hydrochloride salt |
CN104496940B (zh) * | 2014-01-06 | 2017-03-15 | 广东东阳光药业有限公司 | 一种制备bcr‑abl抑制剂中间体的方法 |
CN106146391A (zh) * | 2015-04-15 | 2016-11-23 | 中国科学院上海药物研究所 | 5-芳香炔基取代的苯甲酰胺类化合物及其制备方法、药物组合物和用途 |
JP6570776B2 (ja) * | 2016-06-20 | 2019-09-04 | テグ−キョンプク メディカル イノベーション ファウンデーション | 新規のイミダゾピリジン誘導体、その製造方法及びこれを有効成分として含有する癌の予防又は治療用医薬組成物 |
WO2020013531A1 (ko) * | 2018-07-10 | 2020-01-16 | 보로노이바이오 주식회사 | N-(3-(이미다조[1,2-b]피리다진-3-일에티닐)-4-메틸페닐)-5-페닐-4,5-다이하이드로-1H-피라졸-1-카복사마이드 유도체 및 이를 유효성분으로 포함하는 키나아제 관련 질환 치료용 약학적 조성물 |
US11746110B2 (en) | 2018-07-17 | 2023-09-05 | Shenzhen Targetrx, Inc. | Alkynyl (hetero) aromatic ring compounds used for inhibiting protein kinase activity |
CN113825543A (zh) | 2019-03-19 | 2021-12-21 | 勃林格殷格翰动物保健美国公司 | 驱虫的氮杂-苯并噻吩和氮杂-苯并呋喃化合物 |
WO2020214999A1 (en) * | 2019-04-17 | 2020-10-22 | Emory University | Abelson non-tyrosine kinase compounds for the treatment of neurodegenerative diseases |
CN111004240B (zh) * | 2019-12-13 | 2020-12-01 | 山东铂源药业有限公司 | 一种泊那替尼中间体3-乙炔基咪唑并[1,2-b]哒嗪的合成方法 |
US20230295153A1 (en) * | 2020-02-28 | 2023-09-21 | Daegu-Gyeongbuk Medical Innovation Foundation | 3-((8-((1h-pyrazol-4-yl)amino)imidazo[1,2-a]pyridin-3-yl)ethinyl)-n-phenylbenzamide derivative, method for preparing same, and pharmaceutical composition containing same as active ingredient for prevention or treatment of cancer |
MX2022015038A (es) | 2020-05-29 | 2023-01-04 | Boehringer Ingelheim Animal Health Usa Inc | Compuestos heterociclicos como anthelminticos. |
EP4324833A1 (en) * | 2021-04-13 | 2024-02-21 | Shenzhen Newdel Biotech Co., Ltd. | Alkynylphenylbenzamide compound and use thereof |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6841567B1 (en) * | 1999-02-12 | 2005-01-11 | Cephalon, Inc. | Cyclic substituted fused pyrrolocarbazoles and isoindolones |
WO2002079459A2 (en) * | 2001-03-29 | 2002-10-10 | Nsgene A/S | Means for inhibiting proteolytical processing of parkin |
DE10360793A1 (de) * | 2003-12-23 | 2005-07-28 | Grünenthal GmbH | Spirocyclische Cyclohexan-Derivate |
CN101389338B (zh) * | 2005-12-23 | 2013-06-26 | 阿里亚德医药股份有限公司 | 双环杂芳基化合物 |
ES2761180T3 (es) * | 2005-12-23 | 2020-05-19 | Ariad Pharma Inc | Compuestos bicíclicos de heteroarilo |
-
2012
- 2012-04-06 EA EA201391486A patent/EA201391486A1/ru unknown
- 2012-04-06 BR BR112013024169A patent/BR112013024169A2/pt not_active Application Discontinuation
- 2012-04-06 CA CA2832465A patent/CA2832465A1/en not_active Abandoned
- 2012-04-06 CN CN201280027388.3A patent/CN103596568A/zh active Pending
- 2012-04-06 KR KR1020137029633A patent/KR20140022062A/ko not_active Application Discontinuation
- 2012-04-06 AU AU2012363094A patent/AU2012363094A1/en not_active Abandoned
- 2012-04-06 MX MX2013011589A patent/MX2013011589A/es not_active Application Discontinuation
- 2012-04-06 EP EP12861665.3A patent/EP2694066A1/en not_active Withdrawn
- 2012-04-06 WO PCT/US2012/032544 patent/WO2013101281A1/en active Application Filing
- 2012-04-06 US US14/009,511 patent/US20140066434A1/en not_active Abandoned
- 2012-04-06 JP JP2014504027A patent/JP2014513078A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
KR20140022062A (ko) | 2014-02-21 |
MX2013011589A (es) | 2013-12-16 |
EP2694066A1 (en) | 2014-02-12 |
CN103596568A (zh) | 2014-02-19 |
JP2014513078A (ja) | 2014-05-29 |
US20140066434A1 (en) | 2014-03-06 |
EA201391486A1 (ru) | 2014-09-30 |
WO2013101281A1 (en) | 2013-07-04 |
CA2832465A1 (en) | 2013-07-04 |
AU2012363094A1 (en) | 2013-09-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112013024169A2 (pt) | método para o tratamento e prevenção da doença de parkinson | |
IL266648B (en) | A method for treating Parkinson's disease | |
BR112013007678A2 (pt) | método para tratamento de doenças alérgicas | |
CO6940374A2 (es) | Composiciones, usos y métodos para tratamiento de trastornos y enfermedades metabólicas | |
BR112014010299A2 (pt) | composição para prevenir e tratar doenças da cavidade oral; método de prevenção e tratamento de doenças da cavidade oral; e uso da composição | |
IL237369A0 (en) | Methods for treating Alzheimer's disease and pharmaceutical compositions thereof | |
BR112013018469A2 (pt) | dispositivos e métodos para tratamento de tecidos | |
HK1201196A1 (en) | Treatment of ocular disease | |
BR112014002619A2 (pt) | composição farmacêutica e método de tratamento e/ou prevenção de câncer pancreático e combinação farmacêutica | |
DK2877184T3 (da) | Sammensætninger og behandling for øjensygdomme og -lidelser | |
UY33863A (es) | Metodos y medicamentos para el tratamiento de la enfermedad de alzheimer | |
EP2819687A4 (en) | COMPOSITIONS AND METHODS FOR TREATING PERIPHERAL VASCULAR DISEASE | |
DK2747763T3 (da) | (bacterio-)chlorofyllfotosensibilisatorer til behandling af øjensygdomme og -lidelser | |
HK1200348A1 (en) | Methods and materials for treatment of pompes disease | |
PL2701645T3 (pl) | Urządzenie do leczenia i/lub zapobiegania chorobom rogówki | |
EP2691529A4 (en) | METHOD AND COMPOSITIONS FOR TREATING BRAIN DISEASES | |
IL234606B (en) | Innovative methods and compounds for the treatment of diseases | |
BR112014004416A2 (pt) | composições e métodos para o tratamento de doenças neurodegenerativas | |
EP2623494A4 (en) | AGENT FOR THE TREATMENT OF OCULAR DISEASES | |
BR112013030370A2 (pt) | compostos de quinona para tratamento de doenças mediadas por ape1 | |
ES2627541T8 (es) | Métodos para tratar la enfermedad de Parkinson | |
IL229705A0 (en) | Methods for the treatment or prevention of neurological diseases | |
BR112013034066A2 (pt) | método de administração e tratamento | |
BR112014013807A2 (pt) | composição de condicionamento de tecidos e processo para o tratamento de tecido | |
EP2709632A4 (en) | COMPOSITIONS AND METHOD FOR THE TREATMENT OF SKIN DISEASES |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B15I | Others concerning applications: loss of priority |
Free format text: PERDA DA PRIORIDADE US 61/472,961 DE 07/04/2011, CONFORME AS DISPOSICOES PREVISTAS NA LEI 9.279 DE 14/05/1996 (LPI) ART. 16 7O E NO ART. 29 DA RESOLUCAO INPI-PR 77/2013, POR NAO ATENDER AO DISPOSTO NO ART. 28 DA RESOLUCAO INPI-PR 77/2013, POIS NAO FOI APRESENTADA CESSAO DA REFERIDA PRIORIDADE, QUE POSSUI DEPOSITANTE DIFERENTE DO DEPOSITANTE DA FASE NACIONAL. |
|
B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] |